Editor's Pick: Markets: The week that was (16-20/11/09)
(RB-.L) Reckitt Benckiser Group PLC Buy/Sell
3130.50
-11.00
(-0.35%)
Add to portfolio
Set Alert
Level 2
Desktop Trader
News
Be automatically updated! Get company news by RSS.
Click here for the feed: RSS Feed or learn more about the benefits RSS
| Date/Time | Headline | Source |
|---|---|---|
| 1 | 2 | 3 | ||
| Fri 17:00 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 20 November 2009, the following ordinary shares (8,000) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Executive Share Scheme: 8,000 Ordinary shares at £18.10 per share Following the above transfer of treasury shares, the Company holds 7,237,546 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 715,130,966.
END More |
||
| Thu 17:16 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 19 November 2009, the following ordinary shares (18,000) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Executive Share Scheme: 2,000 Ordinary shares at £15.470 per share 16,000 Ordinary shares at £18.10 per share Following the above transfer of treasury shares, the Company holds 7,245,546 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 715,122,966.
END More |
||
| Wed 16:45 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 18 November 2009, the following ordinary shares (101,893) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Restricted Share Scheme: 100,500 Ordinary shares Executive Share Scheme: 1,261 Ordinary shares at £15.470 per share Global Stock Profit Plan: 132 Ordinary shares at £21.95 per share Following the above transfer of treasury shares, the Company holds 7,263,546 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 715,104,966.
END More |
||
| Tue 16:53 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 17 November 2009, the following ordinary shares (24,469) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Executive Share Scheme: 15,000 Ordinary shares at £11.186 per share 8,000 Ordinary shares at £12.76 per share 1,469 Ordinary shares at £15.47 per share Following the above transfer of treasury shares, the Company holds 7,365,439 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 715,003,073.
END More |
||
| Mon 17:14 | PRN |
|
|
NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification required by DR 3.3 (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. (3) An issuer making a notification in respect of options granted to a director /person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes should in block capital letters.
non-beneficial interest
BENEFICIAL INTEREST ORDINARY SHARES
(s) and, if more than one, the number of shares held by each of them
BART BECHT EXERCISE OF RESTRICTED SHARE RIGHTS
AND TRANSFER BY WAY OF GIFT OF
RESULTING SHARES TO CHARITABLE
TRUST TO BE HELD ON A
transaction
Disposal cost: NIL - gifted to
Trust
notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)
BENEFICIALLY
1,343,821 (0.0019%) HELD
NON-BENEFICIALLY If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes
21. Exercise price (if fixed at time 22. Total number of shares or
of exercise
Name and signature of duly authorised officer of issuer responsible for making notification ELIZABETH RICHARDSON, COMPANY SECRETARY __________________________________________________________ Date of notification 16 NOVEMBER 2009
END More |
||
| Mon 17:08 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 16 November 2009, the following ordinary shares (25,000) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Executive Share Scheme: 25,000 Ordinary shares at £5.538 per share Following the above transfer of treasury shares, the Company holds 7,389,908 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,978,604.
END More |
||
| 13-11-09 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 13 November 2009, the following ordinary shares (1,000) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Executive Share Scheme: 1,000 Ordinary shares at £18.10 per share Following the above transfer of treasury shares, the Company holds 7,414,908 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,953,604.
END More |
||
| 11-11-09 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 11 November 2009, the following ordinary shares (414) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: UK Share Save Scheme: 414 Ordinary shares at £13.71 per share Following the above transfer of treasury shares, the Company holds 7,415,908 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,952,604.
END More |
||
| 10-11-09 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 10 November 2009, the following ordinary shares (21,943) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Executive Share Scheme: 2,000 Ordinary shares at £12.76 per share 289 Ordinary shares at £15.47 per share 18,000 Ordinary shares at £18.10 per share 1,065 Ordinary shares at £22.57 per share US Share Save Scheme: 589 Ordinary shares @ £21.95 per share Following the above transfer of treasury shares, the Company holds 7,416,322 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,952,190.
END More |
||
| 06-11-09 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 6 November 2009, the following ordinary shares (6,000) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Executive Share Scheme: 4,000 Ordinary shares at £15.47 per share 2,000 Ordinary shares at £18.10 per share Following the above transfer of treasury shares, the Company holds 7,438,265 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,930,247
END More |
||
| 05-11-09 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 5 November 2009, the following ordinary shares (8,000) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Executive Share Scheme: 8,000 Ordinary shares at £12.76 per share Following the above transfer of treasury shares, the Company holds 7,444,265 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,924,247.
END More |
||
| 04-11-09 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 4 November 2009, the following ordinary shares (487) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Global Stock Profit Plan: 487 Ordinary shares at £21.95 per share Following the above transfer of treasury shares, the Company holds 7,452,265 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,916,247.
END More |
||
| 03-11-09 | PRN |
|
|
NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification required by DR 3.3 (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. (3) An issuer making a notification in respect of options granted to a director /person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes should in block capital letters.
SIMON NASH PDMR
non-beneficial interest
BENEFICIAL INTEREST ORDINARY SHARES
(s) and, if more than one, the number of shares held by each of them
SIMON NASH PURCHASE OF SHARES
transaction
notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)
If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes
21. Exercise price (if fixed at time 22. Total number of shares or
of exercise
Name and signature of duly authorised officer of issuer responsible for making notification ELIZABETH RICHARDSON, COMPANY SECRETARY __________________________________________________________ Date of notification 3 NOVEMBER 2009
END More |
||
| 30-10-09 | PRN |
|
|
RECKITT BENCKISER GROUP PLC
In conformity with the Disclosure and Transparency Rules (DTR 5.6.1), at close of business on 30 October, Reckitt Benckiser Group plc: * had 722,368,512 issued ordinary shares of 10p each admitted to trading. Each ordinary share carries the right to one vote in relation to all circumstances at general meetings of Reckitt Benckiser Group plc; * held 7,452,752 ordinary shares in treasury. The voting rights of treasury shares are automatically suspended; and * accordingly, had total voting rights of 714,915,760. The total voting rights figure (714,915,760) may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Reckitt Benckiser Group plc under the FSA's Disclosure and Transparency Rules.
END More |
||
| 29-10-09 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 29 October 2009, the following ordinary shares (52,500) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Executive Share Scheme: 52,500 Ordinary shares at £18.10 per share Following the above transfer of treasury shares, the Company holds 7,452,752 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,915,760.
END More |
||
| 28-10-09 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 28 October 2009, the following ordinary shares (15,350) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Executive Share Scheme: 409 Ordinary shares at £11.186 per share 5,000 Ordinary shares at £15.470 per share 8,000 Ordinary shares at £18.10 per share 1,090 Ordinary shares at £22.57 per share UK Share Save Scheme: 851 Ordinary shares at £13.71 per share Following the above transfer of treasury shares, the Company holds 7,505,252 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,863,260.
END More |
||
| 27-10-09 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 27 October 2009, the following ordinary shares (36,000) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Executive Share Scheme: 36,000 Ordinary shares at £18.10 per share Following the above transfer of treasury shares, the Company holds 7,520,602 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,847,910.
END More |
||
| 27-10-09 | PRN |
|
|
Reckitt Benckiser Group plc
CONTINUED STRONG MOMENTUM IN Q3
FY 2009 TARGETS INCREASED
(unaudited)
Profit -
reported
Profit -
adjusted *
reported
adjusted *
EPS (diluted) 49.6p +26 134.4p +30
Year to date ("YTD") highlights:
net revenue was ahead +5% (at constant).
Q3 highlights:
Commenting on these results, Bart Becht, Chief Executive Officer, said: "Reckitt Benckiser continued to see good momentum, with net revenue growth of +7% at constant exchange. This result was supported by our 17 Powerbrands, behind significant investment in media and marketing and successful new product initiatives. We are raising our full year target for net revenue growth to +6-7% at constant exchange (previously +5-6%), as a result of continued strong momentum in the base business, combined with upside on RBP compared to ingoing expectations. For adjusted net income growth, we are raising our target to +12-13% at constant exchange (previously +10-11%), or around +22-23% at actual exchange."
Where appropriate, the term "adjusted" excludes the impact of exceptional items. There are no exceptional items in YTD 2009, compared to an exceptional charge in YTD 2008 of £30m mainly relating to the integration of Adams.
Third quarter 2009 Q3 net revenue increased +15% to £1,907m, with growth of +7% at constant exchange. The gross margin improved by +120bp to 60.0%, largely as a result of easing input costs and benefits from cost optimisation programmes, partially offset by a negative transaction impact from foreign exchange. While media activity increased, media spend declined by -5% (-9% constant) to a level of 10.4% of net revenue due to further improvements in media buying rates. Total marketing investment was higher, as savings from these more favourable media rates were re-invested in Other Consumer Marketing activities. Operating profit as reported was £467m, +23% higher than last year (+10% constant): the operating margin increased by +170bp to 24.5% due to gross margin expansion and operating cost efficiencies. Net finance income was £2m (Q3 2008: net finance expense of £7m), reflecting strong free cash flow generation and progress made on net debt repayment during the quarter. The tax rate was 24%. Net income was £357m, an increase of +25% (+12% constant) on both a reported and adjusted basis versus Q3 2008. Year to date (nine months) 2009 YTD net revenue increased +20% to £5,690m, with growth of +7% at constant exchange. The gross margin improved by +90bp to 59.4%, largely as a result of easing input costs and benefits from cost optimisation programmes, partially offset by a negative transaction impact from foreign exchange. Total marketing investment was higher, and pure media investment rose +5% (-5% constant) to a level of 11.5% of net revenue. There was significant growth in Other Consumer Marketing, funded by savings from more favourable media rates. Operating profit as reported was £1,286m, +31% higher than last year (+15% constant): on an adjusted basis, operating profit was ahead +27% (+12% constant). The adjusted operating margin increased by +130bp to 22.6% due to gross margin expansion and operating cost efficiencies. Net finance expense was £1m (YTD 2008: £26m), reflecting strong free cash flow generation and progress made on net debt repayment during the nine months. The tax rate was 25%. Net income was £970m, an increase of +33% (+16% constant) on YTD 2008. On an adjusted basis, net income was up +29% (+13% constant).
Summary: % net revenue growth
The Business Review below is given at constant exchange rates.
YTD 2009 total net revenue increased +1% to £2,644m, with growth mainly in Dishwashing, Home Care and Health & Personal Care. The continued success of Quantum contributed to growth in Dishwashing, with such initiatives as Airwick Freshmatic, Freshmatic Mini and <i>motion supporting the result in Air Care. In Health & Personal Care, increased marketing investment helped drive a strong performance for Nurofen, Strepsils and Gaviscon. For the nine months, the adjusted operating margin was +20bp ahead of last year at 22.7%; this resulted in a +1% improvement in adjusted operating profit to £ 600m. In Q3, net revenue growth was unchanged at £862m. Adjusted operating profit increased by +1% to £197m, with the margin up +40bp to 22.9%.
YTD 2009 total net revenue increased +7% to £1,546m, with growth coming largely in Surface Care, Home Care and Health & Personal Care. Growth in Surface Care was boosted by increased consumption of Lysol spray and disinfectant wipes, while Airwick Freshmatic and <i>motion contributed to the result in Home Care. In Health & Personal Care, growth was driven by Mucinex. In Food, the consumer portfolio delivered a good performance, with further growth in particular for French's Yellow Mustard and Frank's Red Hot Sauce. For the nine months, adjusted operating profit increased +11% to £303m; the adjusted operating margin was +90bp higher at 19.6%. Q3 net revenue rose +6% to £538m and adjusted operating profit was ahead by +6% to £134m, equating to a +130bp uplift in the margin to 24.9%.
YTD 2009 total net revenue was ahead +15% to £1,106m, with growth across all regions and driven particularly by Fabric Care, Surface Care and Health & Personal Care. Growth in Fabric Care was driven by a strong performance for Vanish, behind increased marketing investment and new initiatives. Surface Care increased largely as a result of growth in Harpic, and Veja in Brazil. In Health & Personal Care, the Dettol personal care range delivered an excellent result, boosted by additional marketing investment, with Veet and Gaviscon also strong contributors. For the nine months, adjusted operating profit increased by +20% to £146m. This resulted in a +80bp improvement in the adjusted operating margin to 13.2%. Q3 net revenue increased by +15% to £367m. Adjusted operating profit improved +17% to £48m, with a +90bp uplift in the margin to 13.1%.
YTD 2009 total net revenue for the Group's Subutex and Suboxone prescription drug business grew +42% to £394m. These buprenorphine-based products are used to treat opiate dependence. This very strong growth was predominantly driven by a continued increase in penetration of Suboxone in the U.S. For the nine months, the adjusted operating margin improved by +300bp to 60.2%. Adjusted operating profit was £237m, an increase of +45%. Q3 net revenue rose +41% to £140m. Adjusted operating profit increased +44% to £88m, for a +290bp expansion in the margin to 62.9%. As a result of its Orphan Drug Status, Suboxone has exclusivity in Europe until 2016: in the U.S., Suboxone lost exclusivity on 8th October 2009. Within the Pharmaceuticals division, the U.S. Suboxone business generated YTD 2009 net revenue of £342m and adjusted operating profit of £211m. While the Group continues to search for ways to offset the impact of the loss of exclusivity in the U.S., up to 80% of the revenues and profits of that business might be lost in the year following the launch of generic competitors, with the possibility of further erosion thereafter.
Fabric Care. Net revenue decreased -1% to £1,203m. Vanish showed a strong performance in Developing Markets, although the result in Europe and North America & Australia was impacted by increased competitive activity. Woolite also contributed, helped by such new initiatives as Triple Protection and concentrated formulations. Growth was offset by weakness in Laundry Detergents and Fabric Conditioners. Q3 net revenue declined -4% to £396m. Surface Care. Net revenue grew +5% to £963m. Both the Dettol and Lysol ranges delivered strong growth, with Harpic Lavatory Care also performing well, helped by such new initiatives as Harpic liquid with Max Coverage. Q3 growth was +8% to £328m. Dishwashing. Net revenue increased +2% to £628m, helped by the continued success of Finish Quantum. Growth was partially offset by weakness in Dishwashing Additives and higher promotional investment. Q3 net revenue decreased -5% to £188m. Home Care. Net revenue increased +4% to £756m. Growth largely came in Air Care, supported by Airwick Freshmatic, Freshmatic Mini and <i>motion. Q3 growth was +2% to £247m. Health & Personal Care. Net revenue increased +14% to £1,511m. The Dettol personal wash range continued to deliver excellent growth, with Nurofen, Strepsils, Gaviscon and Mucinex all contributing to a strong performance in Healthcare. In Q3, Health & Personal Care grew +16% to £533m. Total Household and Health & Personal Care. Net revenue was ahead by +5% to £ 5,103m. In Q3, total Household and Health & Personal Care grew +4% to £1,706m. Pharmaceuticals. YTD 2009 net revenue for the Group's Subutex and Suboxone prescription drug business grew +42% to £394m, predominantly driven by a continued increase in penetration of Suboxone in the U.S. Adjusted operating profit was ahead +45% to £237m, equating to a +300bp improvement in the margin to 60.2%. Q3 net revenue increased by +41% to £140m, while adjusted operating profit rose +44% to £88m. Food. Net revenue rose +7% to £193m, led by the consumer brands of French's yellow mustard and Frank's Red Hot sauce. Adjusted operating profit increased +18% to £43m. Q3 net revenue grew +7% and adjusted operating profit was £18m (+14%).
Basis of preparation. The unaudited financial information is prepared in accordance with IFRSs as adopted by the European Union and IFRSs as issued by the International Accounting Standards Board, and with the accounting policies set out in the Group's 2008 Annual Report & Financial Statements, except as explained in Note 3 to the Half Year 2009 Condensed Financial Statements. Constant exchange. Movements in exchange rates relative to sterling affect actual results as reported. The constant exchange rate basis adjusts the comparative to exclude such movements, to show the underlying growth of the Group. Net working capital (inventories, short-term receivables and short-term liabilities excluding borrowings and provisions) of minus £1,275m was £178m lower than the 31 December 2008 level, mostly due to an improvement in payables. Net debt as at 30th September 2009 was £423m (December 2008: £1,096m), a decrease of £673m. This reflects ongoing strong net cash flow generation from the business, partially offset by the payment of two dividends totalling £648m. In Q3, net debt decreased £102m compared to the position at the end of June 2009, reflecting strong cash flow generation, partially mitigated by the interim dividend payment (£307m).
The Group is raising its full year target for net revenue growth to +6-7% at constant exchange (previously +5-6%), as a result of continued strong momentum in the base business, combined with upside on RBP compared to ingoing expectations. For adjusted net income growth, the Group is raising its target to +12-13% at constant exchange (previously +10-11%), or around +22-23% at actual exchange. For further information, please contact:
Joanna Speed Director, Investor Relations Andraea Dawson-Shepherd Global Director, Corporate Communications & Affairs
Susan Gilchrist Senior Partner Cautionary note concerning forward-looking statements This document contains statements with respect to the financial condition, results of operations and business of Reckitt Benckiser and certain of the plans and objectives of the Group with respect to these items. These forward-looking statements are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. In particular, all statements that express forecasts, expectations and projections with respect to future matters, including trends in results of operations, margins, growth rates, overall market trends, the impact of interest or exchange rates, the availability of financing to the Company, anticipated cost savings or synergies and the completion of strategic transactions are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors discussed in this report, that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including many factors outside Reckitt Benckiser's control. Past performance cannot be relied upon as a guide to future performance. The Group at a Glance (Unaudited)
2009 2008 2009 2008
2009 2008
Shares in issue
Group Income Statement Analysis (Unaudited)
Segment Information (Unaudited) Analyses by operating segment of net revenue and operating profit, and of net revenue by product group are set out below. The figures for each geographical area show the net revenue and operating profit made by companies located in that area. Additional information is provided to show profit by class of business. Operating segment
Segment Information (Unaudited), continued Product segment
END More |
||
| 21-10-09 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 21 October 2009, the following ordinary shares (194) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: Global Stock Profit Plan: 194 Ordinary shares at £21.95 per share Following the above transfer of treasury shares, the Company holds 7,566,602 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,811,910.
END More |
||
| 15-10-09 | PRN |
|
|
Transfer of Treasury Shares Reckitt Benckiser Group plc ("the Company") announces that, on 15 October 2009, the following ordinary shares (5,621) have been transferred from treasury shares for the purpose of satisfying exercises under the Reckitt Benckiser Group Share Schemes/Plans: US Share Save Scheme: 4,956 Ordinary shares at £16.90 per share 665 Ordinary shares at £21.95 per share Following the above transfer of treasury shares, the Company holds 7,556,796 Ordinary shares in treasury. The total number of ordinary shares in issue (excluding shares held as treasury shares) is 714,811,716.
END More |
||